E. Moon

发表

AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions.

F. Rösch, B. Klasen, E. Moon, 2021, Nuclear medicine and biology.

AAZTA5-squaramide ester: promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions

F. Rösch, B. Klasen, E. Moon, 2020 .

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

F. Rösch, I. De Meester, S. Staelens, 2020, EJNMMI Radiopharmacy and Chemistry.

A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy

M. Yadav, F. Roesch, C. Bal, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[68Ga]Ga-DATA5m.SA.FAPi PET/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor Imaging

G. Kristiansen, G. Feldmann, M. Essler, 2020, Nuklearmedizin.

Biodistribution, pharmacokinetics, dosimetry of [68Ga]Ga-DOTA.SA.FAPi, and the head-to-head comparison with [18F]F-FDG PET/CT in patients with various cancers

M. Yadav, F. Roesch, C. Bal, 2020, European Journal of Nuclear Medicine and Molecular Imaging.

Impact of prompt gamma emission of 44Sc on quantification in preclinical and clinical PET systems.

H. Buchholz, F. Rösch, M. Schreckenberger, 2021, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

First-in-Human Experience With 177Lu-DOTAGA.(SA.FAPi)2 Therapy in an Uncommon Case of Aggressive Medullary Thyroid Carcinoma Clinically Mimicking as Anaplastic Thyroid Cancer.

F. Rösch, R. Sahoo, M. Yadav, 2022, Clinical nuclear medicine.

Fibroblast activation protein inhibitor (FAPi) positive tumour fraction on PET/CT correlates with Ki-67 in liver metastases of neuroendocrine tumours

G. Kristiansen, G. Feldmann, R. Bundschuh, 2021, Nuklearmedizin - NuclearMedicine.

Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA5m chelators

F. Rösch, I. De Meester, S. Staelens, 2020, EJNMMI Radiopharmacy and Chemistry.

Effect of the versatile bifunctional chelator AAZTA5 on the radiometal labelling properties and the in vitro performance of a gastrin releasing peptide receptor antagonist

A. Afshar-Oromieh, A. Rominger, F. Rösch, 2020, EJNMMI Radiopharmacy and Chemistry.

68Ga, 44Sc and 177Lu-labeled AAZTA5-PSMA-617: synthesis, radiolabeling, stability and cell binding compared to DOTA-PSMA-617 analogues

K. Kopka, F. Rösch, U. Bauder-Wüst, 2020, EJNMMI Radiopharmacy and Chemistry.

New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress

A. Afshar-Oromieh, A. Rominger, F. Rösch, 2021, Pharmaceuticals.

Novel Fibroblast Activation Protein Inhibitor-Based targeted Theranostics for Radioiodine Refractory differentiated Thyroid Cancer Patients: A Pilot Study.

R. Sahoo, M. Yadav, S. Agarwal, 2021, Thyroid : official journal of the American Thyroid Association.

From Automated Synthesis to In Vivo Application in Multiple Types of Cancer—Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi

F. Rösch, R. Baum, C. Landvogt, 2022, Pharmaceuticals.

First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2

M. Yadav, C. Bal, E. Moon, 2021, Pharmaceuticals.

68Ga-DOTA.SA.FAPI as a Potential, Noninvasive Diagnostic Probe for Recurrent and Metastatic Adrenocortical Carcinoma: A Head-to-Head Comparison With 18F-FDG.

B. Mittal, J. Shukla, E. Moon, 2023, Clinical nuclear medicine.

In Vitro Evaluation of the Squaramide-Conjugated Fibroblast Activation Protein Inhibitor-Based Agents AAZTA5.SA.FAPi and DOTA.SA.FAPi

F. Rösch, I. De Meester, P. Van der Veken, 2021, Molecules.

Squaric Acid-Based Radiopharmaceuticals for Tumor Imaging and Therapy.

F. Roesch, B. Klasen, E. Moon, 2021, Bioconjugate chemistry.

[111In]In/[177Lu]Lu-AAZTA5-LM4 SST2R-Antagonists in Cancer Theranostics: From Preclinical Testing to First Patient Results

G. Loudos, M. Rouchota, P. Kanellopoulos, 2023, Pharmaceutics.

Translational assessment of a DATA-functionalized FAP inhibitor with facile 68Ga-labeling at room temperature

A. Rominger, F. Rösch, S. Schwarzenböck, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi and [68Ga]Ga-DOTANOC PET/CT imaging for the follow-up surveillance of patients with medullary thyroid cancer.

S. Agarwal, C. Bal, M. Tripathi, 2023, Thyroid : official journal of the American Thyroid Association.

Head-to-Head Comparison between [68Ga]Ga-DOTA.SA.FAPi and [18F]F-FDG PET/CT Imaging in Patients with Breast Cancer

C. Bal, M. Tripathi, E. Moon, 2023, Pharmaceuticals.

Head-to-head comparison of [68Ga]Ga-DOTA.SA.FAPi with [18F]F-FDG PET/CT in radioiodine-resistant follicular-cell derived thyroid cancers

R. Sahoo, S. Agarwal, C. Bal, 2023, European Journal of Nuclear Medicine and Molecular Imaging.

Next generation fibroblast activation protein (FAP) targeting PET tracers - The tetrazine ligation allows an easy and convenient way to 18F-labeled (4-quinolinoyl)glycyl-2-cyanopyrrolidines.

V. Shalgunov, M. Herth, E. Moon, 2023, European journal of medicinal chemistry.

Head-to-Head Comparison of SSTR Antagonist [68Ga]Ga-DATA5m-LM4 with SSTR Agonist [68Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging Study

M. Tripathi, E. Moon, S. Ballal, 2024, Pharmaceuticals.

Tailoring Fibroblast-Activation Protein Targeting for Theranostics: A Comparative Preclinical Evaluation of the 68Ga- and 177Lu-Labeled Monomeric and Dimeric Fibroblast-Activation Protein Inhibitors DOTA.SA.FAPi and DOTAGA.(SA.FAPi)2

A. Afshar-Oromieh, E. Moon, S. Imlimthan, 2024, Molecules.